Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine-Reference-Cited by-同舟云学术

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Published:2018-08-16 Issue:7 Volume:132 Page:761-764
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Manwani Richa¹,Sachchithanantham Sajitha¹,Mahmood Shameem¹,Foard Darren¹,Sharpley Faye¹,Rezk Tamer¹,Lane Thirusha¹,Quarta Cristina¹,Fontana Marianna¹,Lachmann Helen J.¹,Gillmore Julian D.¹,Whelan Carol¹,Hawkins Philip N.¹,Wechalekar Ashutosh D.¹

Affiliation:

1. National Amyloidosis Centre, University College London (Royal Free Campus), Rowland Hill Street, London, United Kingdom

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/7/761/1466773/blood846493.pdf

Reference14 articles.

1. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m-related light chain amyloidosis;Sachchithanantham;J Clin Oncol,2016

2. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients;Terrier;Medicine (Baltimore),2008

3. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone;Palladini;Clin Lymphoma Myeloma Leuk,2011